T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL

Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the long-term, follow-up data from a trial using CAR T-cell therapy in 39 children and young adults with relapsed, treatment-resistant acute lymphocytic leukemia.

Recent Videos
Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
Multidisciplinary Team Is ‘Critical’ in Providing CAR T Therapy for Blood Cancers
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Many Great Treatments Available for MCL But Questions About Sequencing Remain, Expert Says
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says
Key Data on Ziftomenib in Relapsed/Refractory AML and Mutant Subgroups
Key Data on Ziftomenib in Relapsed/Refractory AML and Mutant Subgroups
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Amitkumar Mehta, MD, on Compelling Data From ASH in the Treatment of Lymphoma
Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.
Michael R. Bishop, MD, on Impactful Research in Lymphoma Presented at 2021 ASH
Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for Myeloma
Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
Yael Cohen, MD, on the Safety Profile of Cilta-Cel in Refractory Myeloma
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
Related Content
Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Targeting the Tumor Microenvironment in Lymphoma

Targeting the Tumor Microenvironment in Lymphoma

Stephen M. Ansell, MD, PhD
December 4th 2015
Podcast

In this interview we discuss the role of the tumor microenvironment in Hodgkin and non-Hodgkin lymphoma and research that seeks to disrupt and target this environment as a means of treatment.

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

Selinexor Combo Shows Activity in Myelofibrosis Spleen Responses, Symptoms

Morgan Bayer
December 13th 2024
Article

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

New Developments in Multiple Myeloma

New Developments in Multiple Myeloma

Noopur Raje, MD
December 8th 2014
Podcast

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

NFKB1 Haplotype Boosts Response to Ropeginterferon in MPN Subtypes

NFKB1 Haplotype Boosts Response to Ropeginterferon in MPN Subtypes

Kyle Doherty
December 11th 2024
Article

NFKB1 rs230511 genetic variant improves treatment outcomes for patients with polycythemia vera and essential thrombocythemia.

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Cardiac AEs Decrease With 2nd-Generation BTK Inhibitors in B-Cell Cancers

Ashley Chan
December 9th 2024
Article

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.